Literature DB >> 8433708

Mechanism of interferon-gamma down-regulation of the interleukin 4-induced CD23/Fc epsilon RII expression in human B cells: post-transcriptional modulation by interferon-gamma.

C E Lee1, S R Yoon, K H Pyun.   

Abstract

It has been reported that the interleukin 4 (IL-4) specific induction of cell surface CD23 (Fc epsilon RII) is down-regulated by interferon-gamma (IFN-gamma) in monocytes and B cells. However, the molecular level at which the inhibition occurs seems to vary depending on the cell types. In normal human B cells, IFN-gamma inhibits the IL-4 induced de novo synthesis of CD23 at the level of gene expression. Analysis of inhibition kinetics suggested a rapid signal transmission by IFN-gamma. Yet the inhibitory action of IFN-gamma on CD23 mRNA accumulation appeared as a secondary response requiring a new protein synthesis. Through nuclear run-on transcription and mRNA stability studies, we further demonstrate that the IL-4 induced CD23 gene expression is down-regulated by IFN-gamma mainly at post-transcriptional levels by decreasing mRNA stability.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8433708     DOI: 10.1016/0161-5890(93)90058-j

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  3 in total

1.  Pim serine/threonine kinases regulate the stability of Socs-1 protein.

Authors:  X Peter Chen; Julie A Losman; Simone Cowan; Elizabeth Donahue; Scott Fay; Bao Q Vuong; Martijn C Nawijn; Danielle Capece; Victoria L Cohan; Paul Rothman
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-19       Impact factor: 11.205

2.  Hepatitis B virus RNA-binding proteins associated with cytokine-induced clearance of viral RNA from the liver of transgenic mice.

Authors:  T Heise; L G Guidotti; V J Cavanaugh; F V Chisari
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

3.  Distinct modulation by interferon-gamma (IFN-gamma) of CD23 expression on B and T lymphocytes of atopic subjects.

Authors:  M Corominas; M Mestre; J Bas; E Buendia
Journal:  Clin Exp Immunol       Date:  1998-05       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.